Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.DiaMedica, a drug discovery and clinical development company focused on treatments for type 2 diabetes, has appointed Richard Pilnik to its board of directors.
Subscribe to our email newsletter
Mr Pilnik has spent the past 25 years with Eli Lilly, most recently as group vice president and chief marketing officer and a member of the company’s operations committee and senior management council. Prior to this, Mr Pilnik was president of Lilly Europe for Middle East and Africa operations.
Rick Pauls, president and CEO of DiaMedica, said: “We are delighted with the addition of Mr Pilnik to our board of directors. Mr Pilnik is a very well-respected individual who brings extensive leadership and industry experience in the pharmaceutical sector. Eli Lilly has been a leader in diabetes care for over 80 years and Mr Pilnik’s background will be an exceptional asset to DiaMedica.”